Skip to main content

Table 1 Clinical, epidemiological, and virological characteristics of HIV and HIV/HCV-coinfected patients

From: HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

  HIV HIV/HCV p-value
No 27 28  
Age (years) 51 (46; 53) 48.5 (45.5; 53) 0.272
Gender (male) 16 (59.3%) 19 (67.9%) 0.508
BMI (kg/m2) 25 (23.4; 26.7) 24 (20.8; 26) 0.125
BMI ≥ 25 (kg/m2) 14 (51.9%) 9 (32.1%) 0.139
Diabetes 4 (14.8%) 2 (7.1%) 0.362
High alcohol intake 1 (3.7%) 13 (46.4%)  < 0.001
HIV acquired by IVDU 0 (0%) 22 (78.6%)  < 0.001
Prior AIDS 10 (37%) 8 (28.6%) 0.504
Years since HIV infection   22.5 (17.5; 26.5)
Years since HCV diagnosis   13 (12; 23)
Previous HCV therapy (IFNα + rib)   13 (46.4%)
Antiretroviral therapy 27 (100%) 28 (100%) 0.999
PI-based 6 (22.2%) 6(21.43%) 0.019
2NRTI + II-based 3 (11.1%) 11 (39.3%)  
2NRTI + PI-based 0 (0%) 3 (10.7%)  
2NRTI + NNRTI-based 16 (59.3%) 7 (25%)  
Others 2 (7.4%) 1 (3.6%)  
HIV markers
Nadir CD4 + T-cells 261 (99; 402) 185 (72; 269) 0.155
Nadir CD4 + T-cells < 200 cells/mm3 11 (44%) 15 (53.6%) 0.487
CD4 + T-cells 804 (685; 1036) 678.5 (446.5; 906) 0.026
CD4 + T-cells < 500 cells/mm3 0 (0%) 8 (28.6%) 0.003
HIV-RNA > 50 cp/mL 0 (0%) 0 (0%)
HCV markers
 HCV genotype
  1   18 (64.3%)
  2   1 (3.6%)  
  3   8 (28.6%)  
  4   1 (3.6%)  
  Log10 HCV-RNA (IU/mL)   6.3 (5.8; 6.6)
  HCV-RNA > 850.000 IU/mL   19 (67.9%)
 Non-invasive fibrosis indexes
  FIB-4 1 (0.9; 1.2) 2.6 (1.9; 3.2)  < 0.001
  FIB-4 ≥ 3.25 0 (0%) 7 (25%) 0.006
  LSM (Kpa)   11.9 (9.7; 19.2)
  F0–F1 (< 7.1 kPa)   2 (7.1%)
  F2 (7.1–9.4 kPa)   5 (17.9%)  
  F3 (9.5–12.4 kPa)   8 (28.6%)  
  F4 (≥ 12.5 kPa)   13 (46.4%)  
  1. Statistics: The values are expressed as the absolute number (percentage) and median (interquartile range). P-values were calculated by Mann–Whitney and chi-squared tests
  2. HCV, hepatitis C virus; HCV-RNA, HCV plasma viral load; HIV, human immunodeficiency virus; LSM, liver stiffness measure; HIV-RNA, HIV plasma viral load; IVDU, intravenous drug user; AIDS, acquired immune deficiency syndrome; IFNα + rib, interferon-alpha plus ribavirin; NNRTI, non-nucleoside analogue HIV reverse transcriptase inhibitor; NRTI, nucleoside analogue HIV reverse; BMI, body mass index